Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | GCK | P35557 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11299704 | 0.89 | HTT (0.58) | HTTTDP1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2664261 | 0.88 | SMN1; SMN2 (0.52) | PTGS2HTTTDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL11301173 | 0.87 | HTT (0.56) | HTTTDP1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL425840 | 0.84 | XDH (0.46) | PTGS2HTTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL423993 | 0.83 | ENPP2 (0.47) | PTGS2HTTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11292839 | 0.82 | PKM (0.51) | HTTTDP1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10950514 | 0.81 | PTGS2 (0.54) | PTGS2HTTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2664245 | 0.81 | ENPP2 (0.48) | PTGS2HTTTDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL9071204 | 0.79 | MEN1 (0.46) | PTGS2HTTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11299866 | 0.79 | HTT (0.51) | HTTTDP1L3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812048-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | PTGS2 3643/4885HTT 1623/4885TDP1 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.